Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Company profile
Ticker
VTRS, 0A5V
Exchange
Website
CEO
Mr. Scott Andrew Smith
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Upjohn Inc
SEC CIK
Corporate docs
Subsidiaries
Agila Australasia Pty Ltd • Alphapharm Pty. Ltd. • Mylan Australia Holding Pty Ltd • Mylan Australia Pty Limited • Upjohn Australia Pty Ltd • Viatris Pty. Ltd. • Arcana Arzneimittel GmbH • Mylan Österreich GmbH • Viatris GX BV • Viatris BV ...
IRS number
834364296
VTRS stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
27 Sep 24
8-K
Viatris Announces Cash Tender Offers for Certain Outstanding Notes1
4 Sep 24
10-Q
2024 Q2
Quarterly report
8 Aug 24
8-K
Viatris Reports Second Quarter Financial Results for 2024
8 Aug 24
8-K
Completion of Acquisition or Disposition of Assets
3 Jul 24
8-K
Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors
3 Jun 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges
9 May 24
10-K/A
2023 FY
Annual report (amended)
26 Apr 24
10-K
2023 FY
Annual report
28 Feb 24
Transcripts
VTRS
Earnings call transcript
2024 Q2
8 Aug 24
VTRS
Earnings call transcript
2024 Q1
9 May 24
VTRS
Earnings call transcript
2023 Q3
7 Nov 23
VTRS
Earnings call transcript
2023 Q2
7 Aug 23
VTRS
Earnings call transcript
2023 Q2
7 Aug 23
VTRS
Earnings call transcript
2023 Q1
8 May 23
VTRS
Earnings call transcript
2022 Q4
27 Feb 23
VTRS
Earnings call transcript
2022 Q3
7 Nov 22
VTRS
Earnings call transcript
2022 Q2
8 Aug 22
VTRS
Earnings call transcript
2022 Q1
9 May 22
Latest ownership filings
4
Rajiv Malik
13 Sep 24
4
Rajiv Malik
30 Aug 24
4
Rajiv Malik
23 Aug 24
144
Notice of proposed sale of securities
20 Aug 24
4
Rajiv Malik
17 Jun 24
144
Notice of proposed sale of securities
13 Jun 24
4
Coelho Rogerio Vivaldi
4 Jun 24
3
Coelho Rogerio Vivaldi
4 Jun 24
4
Brian Roman
28 May 24
144
Notice of proposed sale of securities
28 May 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 918.50 mm | 918.50 mm | 918.50 mm | 918.50 mm | 918.50 mm | 918.50 mm |
Cash burn (monthly) | 32.47 mm | (no burn) | 79.97 mm | 36.55 mm | (no burn) | (no burn) |
Cash used (since last report) | 121.91 mm | n/a | 300.28 mm | 137.25 mm | n/a | n/a |
Cash remaining | 796.59 mm | n/a | 618.22 mm | 781.25 mm | n/a | n/a |
Runway (months of cash) | 24.5 | n/a | 7.7 | 21.4 | n/a | n/a |
Institutional ownership, Q2 2024
81.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 970 |
Opened positions | 112 |
Closed positions | 105 |
Increased positions | 304 |
Reduced positions | 357 |
13F shares | Current |
---|---|
Total value | 9.23 tn |
Total shares | 976.46 mm |
Total puts | 2.15 mm |
Total calls | 2.63 mm |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 140.32 mm | $1.49 tn |
BLK BlackRock | 92.67 mm | $985.06 bn |
STT State Street | 62.11 mm | $660.23 bn |
Davis Selected Advisers | 57.54 mm | $611.61 bn |
T. Rowe Price | 56.82 mm | $604.03 mm |
Pacer Advisors | 38.31 mm | $407.25 bn |
IVZ Invesco | 30.71 mm | $326.49 bn |
Geode Capital Management | 29.00 mm | $307.45 bn |
AMP Ameriprise Financial | 21.86 mm | $232.38 bn |
Deerfield Management | 21.40 mm | $227.43 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Sep 24 | Rajiv Malik | Common Stock | Sell | Dispose S | No | No | 11.6563 | 139,681 | 1.63 mm | 505,838 |
12 Sep 24 | Rajiv Malik | Common Stock | Sell | Dispose S | Yes | No | 11.7136 | 60,319 | 706.55 k | 0 |
30 Aug 24 | Rajiv Malik | Common Stock | Sell | Dispose S | Yes | No | 12 | 50,000 | 600.00 k | 60,319 |
28 Aug 24 | Rajiv Malik | Common Stock | Sell | Dispose S | Yes | No | 11.9015 | 50,000 | 595.08 k | 110,319 |
23 Aug 24 | Rajiv Malik | Common Stock | Sell | Dispose S | Yes | No | 11.751 | 100,000 | 1.18 mm | 160,319 |
22 Aug 24 | Rajiv Malik | Common Stock | Sell | Dispose S | Yes | No | 11.7263 | 100,000 | 1.17 mm | 260,319 |
21 Aug 24 | Rajiv Malik | Common Stock | Sell | Dispose S | Yes | No | 11.7526 | 100,000 | 1.18 mm | 360,319 |
14 Jun 24 | Rajiv Malik | Common Stock | Sell | Dispose S | No | No | 10.1789 | 264,300 | 2.69 mm | 645,519 |
13 Jun 24 | Rajiv Malik | Common Stock | Sell | Dispose S | No | No | 10.5153 | 85,660 | 900.74 k | 909,819 |
News
Lexicon Announces Exclusive Licensing Agreement With Viatris For Sotagliflozin In All Markets Outside The U.S. And Europe
16 Oct 24
Viatris Launches Viagra ODF in Canada, A New Dissolvable Erectile Dysfunction Treatment
30 Sep 24
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
24 Sep 24
EXCLUSIVE: Options Expert Warns Of 'Terrible Week' After Friday's Triple Witching
20 Sep 24
Viatris Announces The Pricing Terms Of Cash Tender Offers For All Outstanding Senior Notes Due 2025 Issued By Viatris And Its Subsidiary Mylan, With The Offers Expiring On September 10, 2024
10 Sep 24
Press releases
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe
16 Oct 24
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe
16 Oct 24
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row
8 Oct 24
How Cosmos Health's Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
1 Oct 24
How Cosmos Health's Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
1 Oct 24